多胺生物合成的抑制对转化细胞c—Ha—ras癌基因表达的调控

抗多胺代谢剂－－二氟甲基鸟氨酸（ＤＦＭＯ）作用于经含点突变的Ｈａ－ｒａｓ基因片段转染的转化细胞（ＨＲ－１细胞）引起细胞生长的抑制,其抑制率随ＤＦＭＯ浓度的增加而增大,此时细胞多停滞于Ｇ１期;多胺合成的关键酶鸟氨酸脱羧酶（ＯＤＣ）活性显著下降;Ｈａ－ｒａｓ癌基因ｍＲＮＡ及ｒａｓＰ＾２１蛋白的表达受到抑制;而外源性腐胺与ＤＦＭＯ的同时加入可防止上述一系列改变的发生,说明ＤＦＭＯ使ＨＲ－１细胞某些表型向     

人鼻咽癌细胞基因组中瘤基因Ha－ras－1的Dnase Ⅰ超敏感位点的初步研究

ＤＮａｓｅⅠ超敏感位点的研究能够发现潜在的调控基因转录活化的位点,比较正常人外周血有核细胞,淋巴瘤细胞株Ｐ３ＨＲ１和人鼻咽癌低分化磷癌细胞株ＨＯｎＥ１和ＨＮＥ２中Ｈａ－ｒａｓ－１瘤基因的ＤＮａｓｅⅠ超敏感位点发现,只有ＨＯＮＥ１和ＨＮＥ２细胞基因组中存在一个ＤＮａｓｅⅠ超敏感位点,位于第一个外显子上游０．３７ｋｂ处,上述结果提示正常白细胞和Ｐ３ＨＲ１细胞中Ｈａ－ｒａｓ－１基因处于失活状态,而在鼻咽癌细胞基因组中则处于活化状态,它的活化可能与０．３７ｋｂ处的ＤＮＡ序列有密切的关系。     

SDF－1是Fusin的天然配体

ＳＤＦ－１是Ｆｕｓｉｎ的天然配体美国哈佛医学院ＢｌｅｕｌＣＣ和法国巴斯德研究所ＥｓｔｅｌｌＯｂｅｒｌｉｎ及其同事同时发现了ＨＩＶ－１的共受体Ｆｕｓｉｎ的天然配体为ＣＸＣ类趋化因子基质细胞衍化因子－１（ＳＤＦ－１）,它能阻止ＨＩＶ－１进入细胞并抑制其感...     

毛喉萜抑制人胃癌细胞BGC－823增殖与ras基因表达相关性研究

毛喉萜（ｆｏｒｓｋｏｌｉｎ）对人胄癌细胞ＢＧＣ－８２３增殖有明显抑制作用,具药物剂量和作用时间之依赖性。剂量为２×１０~（－５）ｍｏｌ／Ｌ之毛喉萜使胃癌细胞在软琼脂中形成集落的能力显著降低;癌基因ｃ－Ｈａ－ｒａｓ之表达明显被抑制,细胞核中与ｒａｓ基因上游调控区２．５ｋｂ片段结合的三种蛋白结合能力下降。联系到以同样浓度药物处理胃癌细胞７２ｈ,细胞质、膜与细胞核中蛋白激酶Ｃ（ＰＫＣ）活性均下降的现象,可能ＰＫＣ活性下降与Ｈａ－ｒａｓ基因上游片段２．５ｋｂ结合蛋白之结合能力下降存在相关性,ＰＫＣ可能通过影响ＤＮＡ结合蛋白的磷酸化作用,导致了Ｈａ－ｒａｓ基因表达之被阻抑。而ｒａｓ基因表达下降可能是毛喉萜抑制胃癌细胞增殖的一个重要分子事件。     

二甲亚砜与维甲酸对人卵巢癌细胞COC1的生长抑制及转化生长因子β_1表达的影响

本实验以人卵巢癌细胞株（ＣＯＣ１）为模型,观察诱导分化剂二甲亚砜（ＤＭＳＯ）与维甲酸（ＲＡ）对该细胞生长增殖、ＤＮＡ合成和转化生长因子β１（ＴＧＦβ１）在细胞内表达的影响。结果显示：ＤＭＳＯ与ＲＡ对人卵巢细胞ＣＯＣ１生长有明显的抑制作用,生长曲线表明作用５天后其生长抑制率分别为６２．７％和４２．１％;３Ｈ－胸腺嘧啶核苷（３Ｈ－ＴｄＲ）掺入实验说明ＤＭＳＯ组与ＲＡ组的单位时间计数率（ＣＰＭ）明显低于对照组（Ｐ＜０．０１）。用药３天后百分掺入抑制率分别为６０．４％与３７．９％,表明ＤＭＳＯ与ＲＡ抑制ＣＯＣ１细胞的ＤＮＡ合成;免疫细胞化学反应表明,ＤＭＳＯ或ＲＡ处理５天后,对照组细胞ＴＧＦβ１表达为阳性,定位于胞浆,而处理组细胞ＴＧＦβ１呈阴性或弱阳性反应。以上结果提示ＤＭＳＯ和ＲＡ对人卵巢癌细胞有一定的诱导分化作用。     

DDPH对猪肺动脉平滑肌细胞PDGF·BB和bFGF表达的影响：免疫细胞化学研究

ＤＤＰＨ［１－（２．６－二甲基苯乙氧基）－２－（３．４二甲氧基苯乙胺基）丙烷盐酸盐］是南京药科大学合成的降压新化合物,也具有降低肺动脉高压和抑制肺动脉平滑肌细胞增殖作用。本实验用细胞培养、免疫细胞化学、图像分析、３Ｈ－ＴｄＲ、细胞周期测定等方法,进一步探讨ＤＤＰＨ对缺氧性肺动脉平滑肌细胞（ＰＡＳＭＣＳ）增殖的抑制机制。结果：缺氧促进肺动脉内皮细胞（ＰＡＥＣｓ）的ＰＤＧＦ·ＢＢ和ｂＦＧＦ两种生长因子的表达（积分光密度ＯＤ值）增高。缺氧内皮细胞条件培养液（ＨＥＣＣＭ）能促进ＰＡＳＭＣＳ的ＰＤＧＦ·ＢＢ的ＯＤ值增高,ｂＦＧＦ的ＯＤ值无明显改变。加药组（ＨＥＣ－ＣＭ＋ＤＤＰＨ）的ＰＤＧＦ·ＢＢ和ｂＦＧＦ的ＯＤ值均显著降低,尤以ＰＤＧＦ·ＢＢ的ＯＤ值减少最多．提示：ＤＤＰＨ能抑制ＨＥＣＣＭ引起ＰＡＳＭＣＳ的ＰＤＧＦ·ＢＢ和ｂＦＧＦ表达增多和细胞增殖。结果与大鼠实验观察相符。     

多胺与激动素对稀脉浮萍离体叶状体衰老的影响

多胺与ＫＴ 都可抑制暗诱导衰老的稀脉浮萍（Ｌｅｍ ｎａ ａｅｑｕｉｎｏｃｔｉａｌｉｓ）离体叶状体的叶绿素损失,且多胺的作用大于ＫＴ。ＫＴ 还显著抑制蛋白质的损失与蛋白酶活性的上升,而多胺对此却无大的影响。０．０５ ｍ ｍ ｏｌ／Ｌ的甲基乙二醛二脒基－腙（ＭＧＢＧ）轻微促进叶绿素和蛋白质的损失。０．０５ ｍ ｍ ｏｌ／Ｌ的ＫＴ 可抑制衰老过程中腐胺（Ｐｕｔ）的上升和亚精胺（Ｓｐｄ）的下降,而对精胺（Ｓｐｍ ）无明显影响。在稀脉浮萍中,精氨酸脱羧酶（ＡＤＣ）活性占优势。ＫＴ 可轻微促进ＡＤＣ 活性,而对鸟氨酸脱羧酶（ＯＤＣ）和Ｓ－腺苷甲硫氨酸脱羧酶（ＳＡＭＤＣ）活性无显著影响。讨论了多胺与细胞分裂素在抑制植物叶片衰老过程中作用途径的可能关系     

多胺在肿瘤研究中的意义

多胺（Ｐｏｌｙａｍｉｎｅ）是一类含二个或二个以上氨基的脂肪族化合物,它包括腐胺（Ｐｕｔｒｅｓｃｉｎｅ,Ｐｕｔ）、精脒（亚精胺）（Ｓｐｅｒｍｉｄｉｎｅ,Ｓｐｄ）、精胺（ｓｐｅｒｍｉｎｅｓｐｍ）。多胺来源于Ｌ－鸟氨酸;鸟氨酸脱羧酶（ＯｒｎｉｔｈｉｎｅＤｅｃａｒｂｏｘｙｌａｓｅ,ＯＤＣ）是多胺合成的限速酶。多胺与细胞的分裂分化、核酸代谢、蛋白质生物合成等有密切关系。细胞外液中浓度升高的多胺主要来源于肿瘤细胞。现已发现神经系统肿瘤、白血病、淋巴瘤、恶性黑色素瘤、肺癌、乳腺癌、消化系统肿瘤、泌尿生殖系统肿瘤病人体液中的多胺含量有不同程度的升高,作为恶性肿瘤辅助诊断、疗效及预后的制定,是一项较好的（临床诊断肿瘤）指标。多胺的分析方法、多胺合成抑制剂、鸟氨酸脱羧酶的调控机制及多胺与癌基因之间关系是值得进一步研究的新颖内容。     

癌基因EJ－ras在小鼠胚胎干细胞（ES－5）中的表达及其对ES－5细胞一些特征的影响

转基因动物在研究基因的功能、医药、畜牧业等方面有重要的应用。利用胚胎干细胞（ＥＳ）制作转基因动物,比传统的显微注射法有无可比拟的优点。但是,目前、只在小鼠中建立起了ＥＳ细胞系,在其它哺乳动物（包括家畜）中尚未建成。近来,人们开始探索：改变胚胎细胞的遗传物质（如：把外源基因导入胚胎细胞）是否有利于获得ＥＳ细胞系．在各种外源基因中,癌基因是值得尝试的基因。因为：（１）ＥＳ细胞的建系是使胚胎的ＩＣＭ细胞永生化的过程;（２）在体外利用癌基因转染可使许多原代培养细胞永生化;（３）ＥＳ细胞高表达一些原癌基因。我们用癌基因ＥＪ－ｒａｓ转染小鼠ＥＳ细胞,观察其对ＥＳ－５细胞一些特性（增殖、嵌合能力）的影响,以便选择合适的癌基因用于家畜ＥＳ细胞的建系。ＥＳ－５细胞通常培养在丝裂霉素处理的小鼠胚胎成纤维细胞（ＭＥＦ）上（Ｆｉｇ．Ａ）。转染用ＥＳ－５细胞培养在无饲养层细胞的、含有大鼠肝细胞（ＢＲＬ）的条件培养液ＤＭＥＭ中。ＥＪ－ｒａｓ基因克隆在真核表达载体ＰＳＶ２ｎｅｏ的ＢａｍＨＩ位点上、使用磷酸钙法转染ＥＳ－５细胞,Ｇ－４１８法筛选阳性克隆,得到的抗性克隆仍以集落形式生长（Ｆｉｇ．Ｂ）,选取５个较好的克隆（ＥＳ－ｒａｓ１,２,     

禾本科植物的起源,进化及分布

禾本科植物的起源、进化及分布韩建国樊奋成李枫（中国农业大学草地研究所,北京１０００９４）ＯＲＩＧＩＮ,ＥＶＯＬＵＴＩＯＮＡＮＤＤＩＳＴＲＩＢＵＴＩＯＮＯＦＴＨＥＧＲＡＭＩＮＥＡＥＨａｎＪｉａｎ－ｇｕｏＦａｎＦｅｎ－ｃｈｅｎｇＬｉＦｅｎｇ（Ｇｒａｓｓｌ...     

The c-Ha-ras oncogene and a tumor promoter activate the polyoma virus enhancer

A c-Ha-ras oncogene, to a lesser extent the c-Ha-ras proto-oncogene, and the tumor promoter 12-O-tetradecanoylphorbol-13-acetate activate the inactive polyoma virus (Py) enhancer in a myeloma cell line and the partially active Py enhancer in NIH 3T3 fibroblasts, but have no effect on the active Py enhancer in LMTK- fibroblasts. In addition, c-Ha-ras can stimulate the inactive Py enhancer in embryonal carcinoma F9 cells. c-Ha-ras activation in embryonal carcinoma cells does not appear to involve reversal of "E1A-like" inhibition of the enhancer. We suggest that modulation of cellular enhancer activity could play a key role in tumorigenesis by oncogenes.     

Differential expression of the major histocompatibility antigen complex (MHC) on a series of Burkitt's lymphoma lines

We compared the expressions of class I and class II major histocompatibility antigen complex (MHC) on the surface of Jijoye and P3HR-1 cells of Burkitt's lymphoma sublines. Jijoye cells had a large amount of class I and class II MHC antigens, whereas these antigens were less expressed on P3HR-1 cells. On a subline of P3HR-1 K cells the expression of class I antigen markedly diminished and class II antigen was undetectable. On the other hand, Jijoye, P3HR-1, and P3HR-1 K cell lines were confirmed to be Epstein-Barr virus (EBV) nonproducer, low producer, and high producer, respectively. The chemical activation of EBV genome by treating P3HR-1 cells with 12-O-tetradecanoyl phorbol-13 acetate (TPA) and n-butyrate resulted in inhibition of the expression of class I and II antigens, while the addition of retinoic acid, an inhibitor of virus replication, blocked the decrease in the MHC antigen expression. These findings suggested that there might be an inverse correlation between the virus production and the expression of class I and II MHC antigens.     

Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells

NIH 3T3 tertiary transfectants containing the N-ras or c-Ha-ras oncogenes derived from human tumors were tested for susceptibility to lymphokine-activated killer (LAK) cell and natural killer (NK) cell lysis. N-ras tertiary transfectants contained a human acute lymphocytic leukemia-derived N-ras oncogene. C-Ha-ras transfectants contained either the position 61-activated form of the oncogene (45.342, 45.322, and 45.3B2) or the position 12-activated form (144-162). In 4 hr 51Cr release assays, seven of seven in vivo grown human oncogene transfected NIH 3T3 fibroblasts were lysed by murine LAK effectors, whereas six of seven were lysed by human LAK effectors. There was no difference in susceptibility to lysis between cells transfected with the N-ras oncogene, the position 61 activated c-Ha-ras oncogene, or the position 12 activated c-Ha-ras oncogene. Cultured NIH 3T3 fibroblasts, as well as in vitro and in vivo grown NIH 3T3 tertiary transfectants were resistant to lysis by murine NK effectors and were relatively resistant (4/6 were not lysed) to lysis by human NK effectors. We conclude that human oncogene-transfected tumors are susceptible to lysis by both murine and human LAK cells while being relatively resistant to lysis by murine and human NK cells. Different oncogenes or the same oncogene activated by different point mutations do not specifically determine susceptibility to lysis by LAK or NK. Also the presence of an activated oncogene does not appear to be sufficient for inducing susceptibility to these cytotoxic lymphocyte populations.     

Transfection of insulin-producing cells with a transforming c-Ha-ras oncogene stimulates phospholipase C activity.

Pancreatic islet beta-cells and insulin-producing RINm5F cells were electroporated in the presence of the c-Ha-ras oncogene, to assess the possible involvement of the encoded product in coupling extracellular receptors to phospholipase C. After two days the c-Ha-ras-transfected cells increased their expression of c-Ha-ras mRNA. These cells were also found to contain more [3H]InsP3, suggesting an increased basal (non-ligand-activated) phospholipase C activity. In addition, the transfected cells were unable to respond to ligand (bombesin) activation of phospholipase C. The ras-transfected insulin-producing cells showed enhanced phosphorylation of a 200 kDa substrate crossreacting with an antibody to an 80 kDa protein kinase C substrate. The phorbol ester 12-O-tetradecanoyl 13-acetate and bombesin also induced phosphorylation of the 200 kDa substrate. All of these changes occurred without changes in the rates of [3H]thymidine incorporation. The results suggest that the mutated c-Ha-ras oncogene directly or indirectly stimulates the basal phospholipase C activity of these cells.     

癌基因Ha-ras在转化和未转化细胞中表达和调控的差异

以前的工作曾用人胃癌基因Ha-ras转化了大鼠全胚细胞系Ratl细胞,得到转化细胞Rat3-3。克隆了Ha-ras癌基因6.6kb及其上游区2.5kb DNA片段,并发现2.5kb有Alu重复顺序,说明这个片段是来源于人胃癌细胞,虽族观察到p21蛋白编码12位点突变,我们又发现转化的Rat3-3细胞的Ha-ras mRNA水平比未转化的Rat1高大约五倍;通过DNase I超敏感实验证明只有转化细胞核中的Ha-ras基因对DNaseI敏感,1μg/mL的DNaseI就有明显的降解,而未转化细胞Rat1细胞核的Ha-ras基因在15μg/mL的DNaseI中也未发现有任何降解;另外还发现转化细胞核有一种能为Ha-ras基因上游区2.5kb特异结合的核蛋白,分子量大约35kD,此核蛋白不能与6.6kb Ha-ras基因本身结合,在未转化细胞中未发现此蛋白。从这些结果推测,癌基因Ha-ras的活化,除了点突变外,还可能存在另一条活化途径,即它的上游区可能有类似增强子的调控区。     

转化相关蛋白p86的鉴定

以转化细胞Rat3-3免疫大鼠,获得单克隆抗体E5(MeAb E5)。其对应抗原耐热,是分子量为86kD的蛋白质(P86)。它在c-Ha-ras癌基因转化的细胞上均有较高的阳性表达,而在其相应的非转化细胞上含量甚微。以人工合成的反义c-Ha-ras寡聚核苷酸As-Ⅱ处理Rat3-3细胞,该细胞生长受抑(44.2％),,此对p86的表达亦降低(39.1％)。P86在五种人胃癌细胞系中均有较高表达,在原发胃癌及其转移灶中阳性率达82.6％。p86不仅是一种与C-Ha-ras转化相关的蛋白,而且为胃癌相关抗原。     

Effect of cellular determination on oncogenic transformation by chemicals and oncogenes.

Three developmentally determined myogenic cell lines derived from C3H 10T1/2 C18 (10T1/2) mouse embryo cells treated with 5-azacytidine were compared with the parental 10T1/2 line for their susceptibility to oncogenic transformation by 3-methylcholanthrene or the activated human c-Ha-ras oncogene. Neither the 10T1/2 cells nor the myogenic derivatives grew in soft agar or formed tumors in nude mice. In contrast to 10T1/2 cells, the three myogenic derivatives were not susceptible to transformation by 3-methylcholanthrene, so that cellular determination altered the response of 10T1/2 cells to chemical carcinogen. On the other hand, all cell types were transformed to a tumorigenic phenotype following transfection with the activated c-Ha-ras gene. The transfected myogenic cells expressed both the c-Ha-ras gene and the muscle determination gene MyoD1. In contrast to other reports, the presence of as many as six copies of the c-Ha-ras gene per genome did not prevent the formation of striated muscle cells which expressed immunologically detectable muscle-specific myosin. The expression of the c-Ha-ras gene does not therefore necessarily preclude the expression of the determination gene for myogenesis or prevent end-stage myogenic differentiation.